Dovato (dolutegravir and lamivudine) is a medicine used for the treatment of Human Immunodeficiency Virus (HIV) infection. It is a combination drug that contains two antiretroviral agents – dolutegravir and lamivudine. This article aims to discuss the uses, benefits, side effects, and warnings related to Dovato.
Uses of Dovato
Dovato is used for the treatment of Human Immunodeficiency Virus (HIV) infection in adults. It is indicated for the initiation of treatment in HIV-1 infected adults who have no previous antiretroviral treatment history or to replace the current antiretroviral regimen in those who have achieved stable viral suppression with no history of treatment failure.
Dovato is not recommended for the treatment of HIV-1 infection in patients who have failed previous antiretroviral therapy due to the risk of developing resistance.
Benefits of Dovato
The combination of dolutegravir and lamivudine in Dovato has been shown to be effective in the treatment of HIV-1 infection. In clinical trials, Dovato has demonstrated non-inferiority to traditional three-drug regimens in terms of viral suppression and tolerability.
Dovato is a once-daily tablet, which may improve treatment adherence and convenience for patients. Additionally, it provides a simplified treatment option for patients with no previous antiretroviral treatment history.
Side Effects of Dovato
Common side effects of Dovato include headache, diarrhea, nausea, and insomnia. Less common side effects include dizziness, abdominal pain, and rash. Serious side effects, such as allergic reactions and liver toxicity, have been reported; however, these are rare.
It is important to note that the combination of dolutegravir and lamivudine in Dovato may not be suitable for all patients. Patients with a history of hypersensitivity reactions to either drug should not take Dovato.
Warnings of Dovato
Dovato has a boxed warning for patients with hepatitis B virus (HBV) infection. The discontinuation of Dovato may result in severe acute exacerbations of HBV. Therefore, patients with HIV-1 and HBV co-infection should be closely monitored for signs of worsening liver function and HBV reactivation during Dovato treatment.
It is also important to note that Dovato should be taken with caution in patients with a history of renal impairment, as dolutegravir has been associated with adverse renal effects.
Dovato should not be used concomitantly with certain medications that may affect dolutegravir plasma concentrations, such as rifampin.
FAQs about Dovato
- What is the dosage for Dovato?
The recommended dosage for Dovato is one tablet once daily with or without food.
- Can Dovato be used in pregnant women?
Dovato should be used in pregnant women only if the potential benefits outweigh the potential risks. It is important to consult a healthcare provider before using Dovato during pregnancy.
- Is Dovato suitable for all patients with HIV-1 infection?
Dovato may not be suitable for all patients with HIV-1 infection. Patients with a history of hypersensitivity reactions to dolutegravir or lamivudine should not take Dovato.
- Can Dovato be used in patients with hepatitis B virus (HBV) infection?
Dovato can be used in patients with HIV-1 and HBV co-infection; however, close monitoring for signs of worsening liver function and HBV reactivation is recommended.
- What should I do if I miss a dose of Dovato?
If a patient misses a dose of Dovato, it should be taken as soon as possible. However, if it is closer to the time for the next dose, patients should skip the missed dose and continue with the regular dosing schedule.
